ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2022 American Transplant Congress » Kidney Immunosuppression: Novel Regimens and Drug Minimization

Date: Tuesday, June 7, 2022

Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

Session Type: Poster Abstract

Meeting: 2022 American Transplant Congress

7:00pm-8:00pm
A Pilot Study Using Registry-Based External Controls for the Cyclosporine Arm of the BENEFIT Study

A. Klein1, D. Stewart2, A. Toll2, W. E. Fitzsimmons1

7:00pm-8:00pm
A Prospective Randomised, Controlled Trial Switching Sirolimus For Mycophenolate To Enhance Immunological Responses To Third Dose Covid-19 Vaccination In Kidney Transplant Recipients With Poor Baseline Humoral Immunity

M. J. Tunbridge1, G. Perkins2, T. Salehi1, B. Grubor-Bauk3, B. Sim1, T. Ying4, J. J. Singer5, S. C. Barry6, P. Hissaria7, S. Chadban8, P. T. Coates1

7:00pm-8:00pm
Adherence, Outcomes and Adverse Effects in Pediatric Renal Transplant Patients After Early Steroid-Withdrawal and Low-Dose Calcineurin Inhibitor Maintenance Immunosuppression

A. Garcia1, R. Plews1, M. Moran1, F. Trujillo1, A. Martinez1, N. Koizumi2, D. Conti1, J. Ortiz1

7:00pm-8:00pm
Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation

N. Fujiyama1, M. Saito2, R. Yamamoto2, R. Sagehashi2, T. Saito2, Y. Aoyama2, K. Numakura2, T. Habuchi2, S. Satoh1

7:00pm-8:00pm
Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy

S. P. Patel, F. Bartlett, T. Sprague, J. Newman, E. Andrade, N. Rao, N. Patel, D. Dubay, V. Rohan, M. Casey, D. Taber

7:00pm-8:00pm
Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity

K. Hotta, N. Iwahara, T. Tanabe, N. Shinohara

7:00pm-8:00pm
De-Novo Belatacept Therapy is Associated with Higher Levels of BK Viremia and Lower Rates of BK Clearance in Kidney Transplantation Patients

G. Petrossian1, J. Ortiz2, K. Addonizio1, L. Teixeira1, A. Hsiao1, R. James3, N. Koizumi3, S. Patel4, D. Conti2, R. Plews2

7:00pm-8:00pm
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients

A. Rizvi1, M. Kueht2, S. Hussain3, J. Fair2, R. Ramirez4, A. Gamilla-Crudo5, M. Mujtaba5

7:00pm-8:00pm
Early Experience with 4-drug Maintenance Immunosuppression in Kidney and Pancreas Transplant Recipients

S. Mouawad1, C. Shoemaker2, J. Geyston3, A. Nishio Lucar3

7:00pm-8:00pm
Early Outcomes of Single Dose Eculizumab for Abo-Incompatible Living Donor Renal Transplantation

K. Heagler, M. Campara, P. Di Cocco, S. Gaitonde, I. Tang, J. Almario Alvarez, M. Spaggiari, J. Benken, C. S. Muran, B. Valdepenas, D. Pierce, I. Tzvetanov, E. Benedetti

7:00pm-8:00pm
Effect of Immunosuppression Withdrawal After Graft Failure on Re-Kidney Transplantation Outcomes

J. Ahn1, S. Sandal2, S. Bae1, D. Segev1, M. McAdams-DeMarco1

7:00pm-8:00pm
Evaluating the Risk and Benefit of Once Daily Delayed Release Mycophenolate in Pediatric Kidney Transplant Recipients

L. Maestretti1, A. McGrath1, A. Fong1, A. Brubaker2, A. Gallo3, P. Grimm3, A. Chaudhuri3

7:00pm-8:00pm
How Does Anti-CD38 Antibody Treatment (Daratumumab) Impact Immunological Assessment in Solid Organ Transplantation?

S. Ho1, K. Putnam2, C. Peiter2, W. Herczyk2, J. Gerlach3, E. Campagnaro4, Y. Lu4, K. Woodside4, M. Cusick4

7:00pm-8:00pm
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study

I. Tawhari1, P. Hallak1, S. Hartzell2, V. Mas3, P. Cravedi2, J. Leventhal1, J. Ansari1, L. Gallon1

7:00pm-8:00pm
Improvement in Kidney Function After Early Conversion to Belatacept-Based Regimen in Allografts with Biopsy-Proven Donor Vascular Disease

T. Ommert1, J. Javier1, J. Jackson1, C. Klein2

7:00pm-8:00pm
Kidney Transplant Recipients with Diabetic Mellitus Demand Larger Doses of Mycophenolate Mofetil

D. Takamoto, H. Sasaki, S. Harada, Y. Takada, H. Harada, T. Tsujimoto

7:00pm-8:00pm
Long-Term Effects of Conversion from Calcineurin Inhibitors to Sirolimus for the Recipients with Low Immunological Risk in Renal Allograft

Q. Wu, J. Chen, D. Cheng, X. Ni, X. Li, K. Xie, W. Jiqiu

7:00pm-8:00pm
Meta-Analysis of the Chronic Exposure to Calcineurin Inhibitors and the Risk for Chronic and End-Stage Kidney Disease in Non-Renal Solid Organ Transplant Recipients

A. Alvarez Elias1, M. Riedl1, D. Stewart2, A. Ruco3, P. Bobos3, S. Maharaj4, V. Shah5, E. Uleryk6, C. Teoh1, R. Parekh1

7:00pm-8:00pm
Optimizing Kidney Transplant Immunosuppression Using a Phenotypic Personalized Dosing Model

J. F. Bruner1, N. Padmanabhan2, C. Ho2, A. Zarrinpar1

7:00pm-8:00pm
Outcomes in Elderly Black Renal Transplant Recipients Receiving Basiliximab Induction and Early Steroid Withdrawal

E. Garcia, T. Sparkes, A. Szczepanik, S. Bova, J. Bromberg, A. Haririan, J. Casale

7:00pm-8:00pm
Outcomes of Very Small Pediatric Donor Kidneys Utilizing Belatacept-Based Immunosuppression in Adult Recipients

K. Heinen1, A. Carlson2, A. Chan1, M. M. Eiting1, T. Larson1, B. Sirandas1, C. Truax1, L. Smith1

7:00pm-8:00pm
Outcomes of a Novel Belatacept-Based Regimen – Beyond 2 Years of Follow-Up

G. Katz-Greenberg1, J. Byrns2

7:00pm-8:00pm
Prevention of the Progression in Chronic Calcineurin Inhibitors Nephrotoxicity via Steroids Anti-Inflammatory Effects

N. Iwahara1, K. Hotta1, Y. Tanaka1, I. Takahashi1, R. Hasebe1, H. Okada1, T. Tsuji2, Y. Takada2, H. Higuchi2, H. Sasaki1, T. Tanabe1, D. Iwami3, N. Shinohara1, M. Murakami1

7:00pm-8:00pm
Randomized, Phase 4 Study Evaluating the Pharmacokinetics and Tolerability of the New Tacrolimus Tablet Formulation (Tacrobell Tab) in Kidney Transplant Recipients

A. Han1, E. Cho1, H. Y. Woo1, C. Ara1, H. Lee2, Y. Kim3, Y. Park4, J. Oh4, S. Min1, J. Ha1

7:00pm-8:00pm
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression

B. Sirandas, A. Chan, M. Eiting, T. Larson, C. Truax, L. Smith

7:00pm-8:00pm
Reduced Dose Mycophenolate Does Not Increase the Risk of Rejection Following Renal Transplantation

L. Bowman1, A. Webb1, S. Desai2, D. Patino3, V. Subramanian4, S. Mohammed5, M. Gosselin6, K. Robichaux5, J. Buggs4, A. Kumar7

7:00pm-8:00pm
The Promise Of Tolerance In Living Donor Kidney Transplant (LDKT): A Retrospective, Real-world Assessment Of The Safety And Efficacy Of LDKT With FCR001 Investigational Cell-therapy Compared With Standard Of Care (SOC)

N. Krieger1, J. R. Leventhal2, B. Ho3, M. Richards4, D. Schaumberg4, S. Ildstad5, D. Axelrod6

7:00pm-8:00pm
The Role Of Gut Microbiome In Optimum Dose Selection Of Tacrolimus For Kidney Transplant Recipients

M. Nayebpour1, N. Koizumi1, J. Melancon2

7:00pm-8:00pm
The Role of Gut Microbiota in Tacrolimus Blood Level Fluctuation, Time in Therapeutic Range and AlloSure Donor Derived Cell-Free DNA, Controlling for CYP3A5

M. Nayebpour1, N. Koizumi1, J. Melancon2, M. Hasan2

7:00pm-8:00pm
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation

E. Siskind1, J. Splinter1, C. Taing1, A. Adekile2, S. Njim1, S. Shah1, R. Plews3, D. Conti4, S. Patel2

7:00pm-8:00pm
Use of Dd-cfdna to Guide Tapering of Immunosuppression Therapy in Kidney Transplant Recipients

G. Osuchukwu1, A. Trevino1, L. Beretich2, S. McCormick2, N. Kaur2, R. White2, P. Gauthier2

7:00pm-8:00pm
Use of De Novo mTOR Inhibitors in Highly Sensitized Kidney Transplant Recipients

J. Bastos1, T. Freesz2, C. Bisi3, C. Marinho2, A. Pires2, V. Colares3, R. Neto2, G. Ferreira2

7:00pm-8:00pm
Viral-Specific Cytotoxic T-Cell Responses in Hla-Sensitized Kidney Transplant Patients Maintained on Everolimus and Low Dose Tacrolimus

R. Zhang1, S. Ge1, M. Chu1, J. Kahwaji2, A. Karasyov1, D. Lovato1, A. Vo2, J. Choi2, M. Toyoda1, S. Jordan2

7:00pm-8:00pm
XR Tacrolimus Dosing By Ideal Body Weight Reduces Incidence Of Early Supratherapeutic Tacrolimus Concentrations

G. Codispodo, J. Hedvat, D. Salerno, N. Lange

« View all sessions from the 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences